ArriVent BioPharma, Inc. AVBP R2KR3KPHARMA
Company Overview
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients. It is also developing ARR-217, an antibody drug conjugate (ADC) for the treatment of gastrointestinal cancers; and ARR-002, ARR-421, and ARR-173 for solid tumors. The company has strategic collaborations with Aarvik Therapeutics Inc., Shanghai Allist Pharmaceuticals Co., Ltd., Beijing InnoCare Pharma Tech Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd., and Lepu Biopharma Co. Ltd. ArriVent BioPharma, Inc. was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.10.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +16.54% |
| 6 Months: | -30.97% |
| 3 Months: | -30.37% |
| 1 Month: | -30.23% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- Death Cross5d ago
- RSI (14)46.30 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 39.5% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | AVBP ArriVent BioPharma, Inc. R2KR3KPHARMA | 21.00 | -5.80 | $1.04B | 0.00% | -57.79% | -53.25% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,273.46 | 42.83 | $1.14T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 263.81 | 30.60 | $635.76B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.64 | 80.69 | $504.76B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 418.09 | 26.85 | $375.28B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 145.27 | 116.22 | $358.41B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 151.12 | 22.83 | $287.24B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 171.49 | 25.63 | $265.96B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 673.82 | 36.30 | $249.14B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | 66.77M | 33.62M | 38.32M | 38.82M | 46.11M |
| Operating Income | -12.17M | -22.58M | -16.72M | -20.67M | -25.70M | - | -66.77M | -33.62M | -38.32M | -38.82M | -46.11M |
| EBITDA | - | - | - | - | - | - | -66.77M | -33.62M | -38.32M | -38.82M | -46.11M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | -64.39M | -31.40M | -34.98M | -35.54M | -43.32M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -12.17M | -21.57M | -14.40M | -17.42M | -21.87M | - | -64.39M | -31.40M | -34.98M | -35.54M | -43.32M |
| Diluted EPS | -9.45 | -10.79 | -5.52 | -0.70 | -0.65 | -0.61 | -1.90 | -0.90 | -0.83 | - | -0.96 |
| R&D Expense | 10.24M | 20.36M | 14.28M | 16.98M | 21.78M | 20.09M | 61.29M | 27.72M | 32.17M | - | 37.62M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - |
| Gross Profit | - | - | - | - |
| Operating Expenses | 36.91M | 74.59M | 94.31M | 177.53M |
| Operating Income | -36.91M | -74.59M | -94.31M | -177.53M |
| EBITDA | -36.91M | -74.59M | -94.31M | -177.53M |
| Interest Expense | - | - | - | - |
| Pretax Income | -36.91M | -69.33M | -80.49M | -166.31M |
| Tax Provision | - | - | - | - |
| Net Income | -36.91M | -69.33M | -80.49M | -166.31M |
| Diluted EPS | -1.15 | -2.17 | -2.56 | -4.32 |
| R&D Expense | - | 64.88M | 79.00M | 153.35M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 182.83M | 163.10M | 274.94M | 333.17M |
| Current Assets | - | 182.62M | 159.97M | 226.98M | 332.90M |
| Cash & Equivalents | - | 163.37M | 150.39M | 74.29M | 45.54M |
| Inventory | - | - | - | - | - |
| Receivables | - | 500.00K | 761.00K | 500.00K | 60.00K |
| Total Liabilities | - | 267.94M | 316.29M | 17.29M | 25.95M |
| Current Liabilities | - | 8.36M | 11.62M | 17.27M | 25.95M |
| Long Term Debt | - | - | - | - | - |
| Total Debt | - | 139.00K | 317.00K | 176.00K | 14.00K |
| Total Equity | - | -85.11M | -153.19M | 257.65M | 307.22M |
| Shares Outstanding | - | 31.96M | 31.96M | 33.71M | 42.45M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Operating Cash Flow | -43.63M | -55.84M | -70.21M | -160.59M |
| Investing Cash Flow | 0 | 0 | -192.47M | -71.23M |
| Financing Cash Flow | 169.72M | 42.86M | 186.58M | 203.06M |
| Capital Expenditure | - | - | - | - |
| Free Cash Flow | -43.63M | -55.84M | -70.21M | -160.59M |
| Net Change in Cash | 126.09M | -12.98M | -76.10M | -28.75M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Gross Margin % | - | - | - | - |
| Operating Margin % | - | - | - | - |
| Net Margin % | - | - | - | - |
| ROE % | 43.4% | 45.3% | -31.2% | -54.1% |
| ROCE % | -21.2% | -49.2% | -36.6% | -57.8% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Montanova Capital LLC | 9.16% | 4.52M | $75.54M |
| 2 | Infinitum Asset Management, LLC | 9.00% | 4.44M | $74.25M |
| 3 | HHLR Advisors, LTD | 7.97% | 3.93M | $65.73M |
| 4 | Blackrock Inc. | 6.59% | 3.25M | $54.38M |
| 5 | Orbimed Advisors LLC. | 6.14% | 3.03M | $50.65M |
| 6 | FMR, LLC | 5.64% | 2.78M | $46.49M |
| 7 | Octagon Capital Advisors LP | 4.00% | 1.97M | $32.98M |
| 8 | Vanguard Capital Management LLC | 3.60% | 1.77M | $29.69M |
| 9 | Sofinnova Investments, Inc. | 3.44% | 1.70M | $28.39M |
| 10 | State Street Corporation | 3.43% | 1.69M | $28.32M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for AVBP
ArriVent BioPharma, Inc. (AVBP) stock price, news, quote and history - Yahoo Finance UK
<a href="https://news.google.com/rss/articles/CBMiUkFVX3lxTE5PNXdfVFpKRHBUNzBrUzFOZkxqR3RfeUxmcTVyM3VZV2tQVHM3ZExNOEhYY2tGRjZvQUVoWmRqdzRVQk5HOXB2QUlJWHRqTHVFSWc?oc=5" target="_blank">ArriVent BioPharma, Inc. (AVBP) stock price, news, quote…
First human data on an experimental cancer drug will be presented in a late-breaking session. - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxOblBxNlVRWTlTU21ZNHNSa0pxSlBaU1ZyZzJNSDRrWEs5MGN1ZmlLVXM3TzV5WFBhT2ZVMGdTX2plT284UFFadFlyNU9vNlFkWGVOVFNZdnpzYXNrNXhPeEFOOXVpVHlmaHE3OUZ1TGx5QmVBMnRTdjBpcWlpc2JjLVN3VGZNbkQ0ejNkd1…
AVBP Stock Crashes More Than 48% To All-Time Low After Lung Cancer Trial Setback – Retail Calls It ‘Way Undervalued’ - Stocktwits
<a href="https://news.google.com/rss/articles/CBMiygFBVV95cUxNUnJlSjB0c1k5ODNVWkNhaS1iczFiTEpLMG1DZVMzYmdYTk4wNkQ3MUxqLWdFcUhDQ1p3eWlrUXEyTWxPcmd2MkdvZEh6eVRvbkloWU5HNHp3b0VWcHVPWUJTb1VkQjRLQ18tTGdXdHYwZ3dtSkc0NWl0bmJrY2hSeFY5WFpPMEhWWlR2LU…
Why Is ArriVent BioPharma Stock Tumbling Today? - ArriVent BioPharma (NASDAQ:AVBP) - Benzinga
<a href="https://news.google.com/rss/articles/CBMi4gFBVV95cUxNcDBubkc0V0JEeGpJTEl2ZUx0RUNLZWJFdEFMX0QycmtkTXh2VWhMLUJzOWxWVUlia1lGZ1g3TmNrU2ZPbkpYeDZQSFdGU2gxTWF1X3hWMFpreEtfem9FY2VTcmYyUFpfaTVhZFd4ZmszV01adTVIdk9paXRreXdaVHhuYVhHODZmR0hMeV…
ArriVent stock plunges on cancer trial failure (AVBP:NASDAQ) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMiiAFBVV95cUxOUU1sY0xKUlVtaDBJME9HOURxWnlCWVcwY0JVSTFXVFgtNEJhaXlxME9NRTRjUEhNSXBKVEhkanhCSFRERHFqRXNpa3puR2F5VDlISjhhcEZOZjdHcEJ1ZUdZNVBWMlRJenZpUlg2NmI0WjM2QVV1RFplOHRnUUlRZW9OdVBtb0ly?oc=5"…
AVBP Nov 2026 17.500 put (AVBP261120P00017500) Stock Price, News, Quote & History - Yahoo! Finance Canada
<a href="https://news.google.com/rss/articles/CBMiZkFVX3lxTFBGTUgydEEyMHRobUlGdUNjcUttNzFPSmFmQXNzcndkNk54MHU1ZHloWlcxcVo4VUNieUFWdmxKYWNFdGNNWnlhV0FtU2tHN2pXT1BlUXVwaFUyRHNhcElua1F6cDhUZw?oc=5" target="_blank">AVBP Nov 2026 17.500 put (AVB…
AVBP — Frequently Asked Questions
What is the current share price of ArriVent BioPharma, Inc. (AVBP)?
As of 2026-10-23 16:27 PDT, ArriVent BioPharma, Inc. (AVBP) trades at $21.00 on NasdaqGM. Its 52-week range is $15.09 to $34.74.
What is the market capitalisation of AVBP?
ArriVent BioPharma, Inc. (AVBP) has a market capitalisation of $1.04B on NasdaqGM.
What is the P/E ratio of AVBP?
AVBP trades at a trailing price-to-earnings (P/E) ratio of -5.80. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is 2.20.
What is the return on equity (ROE) of AVBP?
AVBP has a return on equity (ROE) of -53.25%. Its return on capital employed (ROCE) is -57.79%.
Is AVBP a good stock to buy?
This page provides a data-driven analysis of ArriVent BioPharma, Inc. (AVBP), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.